small molecule drugs: clinical trials
 

We are all aware of the clinical trials with lapatinib but there are a few other small molecule HER inhibitors that are also undergoing clinical trials. The important thing about small molecule drugs is that they cross the blood / brain barrier.
Al

Tarceva (erlotinib)

• Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane, North Central Cancer Treatment Group
• Erlotinib and Bevacizumab (avastin) in Treating Women With Stage IV Breast Cancer. Memorial Sloan-Kettering Cancer Center
• Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/neu Overexpression. Jonsson Comprehensive Cancer Center

Iressa (gefitinib)

• Breast : Gefitinib has very little activity as a single agent in the overall breast cancer population, but preclinical data have suggested synergy with tamoxifen and other hormonal agents, as well as other growth factor inhibitors.
  • A Pilot Trial Incorporating ZD1839 (IRESSA) into Adjuvant Therapy for Breast Cancer - BRE02-43. Hoosier Oncology Group
  • Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer. EORTC
  • Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer. No rris Cotton Cancer Center

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer. Eastern Cooperative Oncology Group (ECOG)